Inventiva S.A.
IVA
NASDAQ·Healthcare·Biotechnology·Mkt cap $248.5M
$4.78
▼ -1.24%
P/E
—
Mkt Cap
$248.5M
52-Wk Range
$3.35–$7.98
52-Week Range
$3.35 - $7.98
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 11.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Oral small molecule approach offering improved patient compliance vs. injectables
- Strategic partnerships with major pharmaceutical companies validating technology
- Advanced clinical pipeline addressing high-unmet-need therapeutic areas
- First-mover advantage potential in emerging NASH treatment market
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
NASH market expansion driven by obesity epidemic and metabolic disorders
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+22.3% over 3m
Quality
Stable
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying IVA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 25, 2026
Most recent quarter reported revenue of $5.2M (+63% YoY). Reported EPS of -$1.90. Gross margin 61.7%.
Reported EPS · last 4Q
Q2 25
-$1.90
Q4 24
-$3.05
Q2 24
-$1.10
Q4 23
-$1.32
Revenue trend · last 6Q
—
—
+7%
-59%
-61%
+63%
Q4 22
Q2 23
Q4 23
Q2 24
Q4 24
Q2 25
$18.1M
$7.8M
$19.4M
$3.2M
$7.6M
$5.2M
Margins · last 6Q
Gross
61.7%
Operating
—
Profit
-3948.8%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · Jul 17, 2026
vs Industry
How IVA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related